SG Americas Securities LLC Makes New Investment in DENTSPLY SIRONA Inc. $XRAY

SG Americas Securities LLC acquired a new position in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 93,071 shares of the medical instruments supplier’s stock, valued at approximately $1,064,000.

Several other hedge funds also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of DENTSPLY SIRONA during the first quarter worth about $26,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of DENTSPLY SIRONA by 337.9% during the third quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock worth $35,000 after buying an additional 2,122 shares during the period. Huntington National Bank boosted its stake in shares of DENTSPLY SIRONA by 292.9% during the third quarter. Huntington National Bank now owns 2,786 shares of the medical instruments supplier’s stock worth $35,000 after buying an additional 2,077 shares during the period. True Wealth Design LLC boosted its stake in shares of DENTSPLY SIRONA by 49.7% during the third quarter. True Wealth Design LLC now owns 3,557 shares of the medical instruments supplier’s stock worth $45,000 after buying an additional 1,181 shares during the period. Finally, Central Pacific Bank Trust Division boosted its stake in shares of DENTSPLY SIRONA by 100.0% during the third quarter. Central Pacific Bank Trust Division now owns 4,000 shares of the medical instruments supplier’s stock worth $51,000 after buying an additional 2,000 shares during the period. Hedge funds and other institutional investors own 95.70% of the company’s stock.

Insider Transactions at DENTSPLY SIRONA

In other news, Director James D. Forbes acquired 5,000 shares of DENTSPLY SIRONA stock in a transaction that occurred on Monday, March 9th. The stock was purchased at an average price of $12.48 per share, for a total transaction of $62,400.00. Following the completion of the transaction, the director directly owned 10,000 shares in the company, valued at approximately $124,800. This trade represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gregory T. Lucier acquired 15,000 shares of DENTSPLY SIRONA stock in a transaction that occurred on Monday, March 9th. The stock was purchased at an average price of $12.45 per share, with a total value of $186,750.00. Following the transaction, the director owned 65,000 shares of the company’s stock, valued at $809,250. This trade represents a 30.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders purchased 70,000 shares of company stock valued at $956,437. 0.50% of the stock is owned by insiders.

DENTSPLY SIRONA Price Performance

Shares of NASDAQ:XRAY opened at $11.99 on Thursday. The company has a quick ratio of 1.03, a current ratio of 1.51 and a debt-to-equity ratio of 1.50. The company has a market cap of $2.40 billion, a P/E ratio of -4.00, a PEG ratio of 1.37 and a beta of 0.99. DENTSPLY SIRONA Inc. has a 52 week low of $9.85 and a 52 week high of $17.18. The company has a 50-day moving average price of $12.42 and a 200 day moving average price of $12.10.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings data on Thursday, February 26th. The medical instruments supplier reported $0.27 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). The firm had revenue of $961.00 million during the quarter, compared to analyst estimates of $926.40 million. DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. DENTSPLY SIRONA’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.26 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Research analysts predict that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on XRAY shares. Barrington Research increased their target price on shares of DENTSPLY SIRONA from $14.00 to $17.00 and gave the stock an “outperform” rating in a research note on Monday, March 2nd. UBS Group decreased their target price on shares of DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. Bank of America upgraded shares of DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and increased their target price for the stock from $13.00 to $17.00 in a research note on Thursday, February 19th. Robert W. Baird increased their target price on shares of DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a “neutral” rating in a research note on Friday, February 27th. Finally, Mizuho increased their target price on shares of DENTSPLY SIRONA from $14.00 to $16.00 and gave the stock a “neutral” rating in a research note on Monday, March 2nd. Three investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $14.42.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.